Targeting the intestinal source
of metabolic disease
A same-day procedural therapy
Understanding the role
of the gut in metabolic disease
Building on New
At Fractyl, we are focused on addressing insulin resistance to improve the health of people with some of the most common metabolic diseases, including type 2 diabetes and non-alcoholic steatohepatitis (NASH).
Our mission is to alleviate the daily burdens of metabolic disease management for patients, empower physicians with a new therapeutic treatment intended to restore metabolic health, and lower the tremendous human and financial costs of metabolic disease complications for patients, hospitals and payers.
With our device-based clinical platform, we are working to transform metabolic disease treatment. Based on new discoveries in metabolic science, our investigational Revita™ duodenal mucosal resurfacing (DMR) procedure targets the upper intestine, or duodenum, with the aim of addressing a root cause of insulin resistance in two common metabolic diseases: